American Diabetes Association Annual Meeting, 1997, and the Teczem Consultant Meeting: Diabetic nephropathy

Diabetes Care

Volumn 21, Issue 2, 1998, Pages 315-319

  Bloomgarden, Zachary T ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; AMLODIPINE PLUS BENAZAPRIL; AMLODIPINE PLUS BENAZEPRIL; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ATENOLOL; BENAZEPRIL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; CILAZAPRIL; CLONIDINE; DIHYDROPYRIDINE DERIVATIVE; DILTIAZEM; DILTIAZEM PLUS ENALAPRIL; DILTIAZEM PLUS ENALAPRIL MALEATE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; ENALAPRIL PLUS FELODIPINE; FELODIPINE; LEXEL; LISINOPRIL; LOW MOLECULAR WEIGHT HEPARIN; NIFEDIPINE; NITRIC OXIDE; RENIN INHIBITOR; TARNA; TRANDOLAPRIL; TRANDOLAPRIL PLUS VERAPAMIL; UNCLASSIFIED DRUG; VERAPAMIL;

ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; COUGHING; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DRUG EFFICACY; DRUG MECHANISM; EDEMA; HEREDITY; HUMAN; HYPERKALEMIA; HYPERTENSION; MICROALBUMINURIA; NEPHROTOXICITY; NONHUMAN; PROTEIN RESTRICTION; REVIEW; RISK FACTOR; UREMIA;

EID: 0031912904     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.21.2.315     Document Type: Review

References (16)

1. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 329:1456-1462, 1993
2. Maschio G, Alberti D, Janin G, Locatelli F, Mann JFE, Motolese M, Ponticelli C, Ritz E, Zucchelli P: Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med 334:939-945, 1996
3. Bakris GL, Copley JB, Vicknair N, Sadler R, Leurgans S: Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy. Kidney Int 50:1641-1650, 1996
4. Klahr S, Levey AS, Beck GJ, Caggiula AW Hunsicker L, Kusek JW, Striker G: The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. N Engl J Med 330:877-884, 1994
5. Pedrini MT, Levey AS, Lau J, Chalmers TC, Wang PH: The effect of dietary protein restriction on the progression of diabetic and nondiabetic renal diseases: a meta-analysis. Ann Intern Med 124:627-632, 1996
6. Parving HH, Andersen AR, Smidt UM, Hommel E, Mathiesen ER, Svendsen PA: Effect of antihypertensive treatment on kidney function in diabetic nephropathy. Br Med J 294:1443-1447, 1987
7. Viberti G, Mogensen CE, Groop LC, Pauls JF: Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. European Microalbuminuria Captopril Study Group. JAMA 271:275-279, 1994
8. Mathiesen ER, Hommel E, Giese J, Parving HH: Efficacy of captopril in postponing nephropathy in normotensive insulin dependent diabetic patients with microalbuminuria. BMJ 303:81-87, 1991
9. Ravid M, Savin H, Jutrin I, Bental T, Katz B, Lishner M: Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med 118:577-581, 1993
10. Rutan GH, Kuller LH, Neaton JD, Wentworth DN, McDonald RH, Smith WM: Mortality associated with diastolic hypertension and isolated systolic hypertension among men screened for the Multiple Risk Factor Intervention Trial. Circulation 77:504-514, 1988
11. Materson BJ, Reda DJ, Cushman WC, Massie BM, Freis ED, Kochar MS, Hamburger RJ, Fye C, Lakshman R, Gottdiener J, Ramirez EA, Henderson WG: Single-drug therapy for hypertension in men: a comparison of six antihypertensive agents with placebo: the Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. N Engl J Med 328:914-921, 1993
12. Materson BJ, Reda DJ, Cushman WC: Department of Veterans Affairs single-drug therapy of hypertension study: revised figures and new data: the Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Am J Hypertens 8:189-192, 1995
13. Mulec H, Johnsen SA, Wiklund O, Bjorck S: Cholesterol: a renal risk factor in diabetic nephropathy? Am J Kidney Dis 22:196-201, 1993
14. Velussi M, Brocco E, Frigato F, Zolli M, Muollo B, Maioli M, Carraro A, Tonolo G, Fresu P, Cemigoi AM, Fioretto P, Nosadini R: Effects of cilazapril and amlodipine on kidney function in hypertensive NIDDM patients. Diabetes 45:216-222, 1996
15. Zucchelli P, Zuccala A, Borghi M, Fusaroli M, Sasdelli M, Stallone C, Sanna G, Gaggi R: Long-term comparison between captopril and nifedipine in the progression of renal insufficiency. Kidney Int 42:452-458, 1992
16. Heeg JE, de Jong PE, van der Hem GK, de Zeeuw D: Efficacy and variability of the antiproteinuric effect of ACE inhibition by lisinopril. Kidney Int 36:272-279, 1989